Literature DB >> 32159126

Lead-Specific Features Predisposing to the Development of Tricuspid Regurgitation After Endocardial Lead Implantation.

Kalilur Anvardeen1,2, Rajeev Rao1,3, Samir Hazra1,4, Karen Hay1, Hongyan Dai1,5, Nik Stoyanov1,6, David Birnie1, Girish Dwivedi1,7, Kwan Leung Chan1.   

Abstract

BACKGROUND: Endocardial lead in the right ventricle is recognized as a cause for tricuspid regurgitation (TR), but the mechanism remains elusive. We sought to evaluate lead-specific features on the development of TR after endocardial lead implantation.
METHODS: This was a prospective single-center study. The patients underwent 2-dimensional echocardiograms before endocardial lead implantation and at follow-up visits at 4 to 6 weeks, 6 months, and 12 months. We assessed the position of the endocardial lead at the tricuspid annulus by 3-dimensional echocardiography, the tricuspid leaflet interference by the endocardial lead by both 2- and 3-dimensional echocardiography, and the degree of lead slack radiologically. Patient characteristics and lead-related factors were evaluated in the prediction of new or worse TR by univariable and multivariable analyses.
RESULTS: New or increased TR was detected in 38 of 128 patients at the 12-month follow-up. The postero-septal commissure was the most common lead position, and tricuspid leaflet interference detected in 21 patients was associated with a noncommissural lead position. The implantation of an implantable cardioverter defibrillator lead was not associated with new TR compared with the implantation of a pacemaker lead. Tricuspid leaflet interference (P < 0.0001), but not lead position or lead slack, was the only lead-specific factor associated with the development of TR.
CONCLUSION: After right ventricle endocardial lead implantation, leaflet interference determined by echocardiography, but not the nature of the lead, the lead position at the tricuspid annulus, and the radiological lead slack, predicted TR development at 1 year postimplantation.
© 2019 Canadian Cardiovascular Society. Published by Elsevier Inc.

Entities:  

Year:  2019        PMID: 32159126      PMCID: PMC7063659          DOI: 10.1016/j.cjco.2019.10.002

Source DB:  PubMed          Journal:  CJC Open        ISSN: 2589-790X


The development of tricuspid regurgitation (TR) after endocardial lead placement into the right ventricle (RV) was reported more than 4 decades ago, and in some patients, severe TR can ensue, necessitating surgical intervention.1, 2, 3, 4, 5 It is increasingly recognized that severe TR is associated with worse survival., With an aging population and the expanding indications for intracardiac devices, TR associated with the endocardial lead will likely become a more important health issue. A wide range of prevalence of TR after endocardial lead placement has been reported.8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 Many of the studies were retrospective in nature with small sample sizes and variable durations of follow-up. Recent studies have suggested that lead location can be assessed by 3-dimensional (3D) echocardiography and appears to be related to the worsening or the new development of TR.19, 20, 21 We have recently shown that new or worse TR occurred in 30% of patients after endocardial lead implantation. The objective of the study was to evaluate lead-specific risk factors for the development of TR after endocardial lead implantation including the nature of the lead (implantable cardioverter defibrillator [ICD] lead vs pacemaker lead), the location of the endocardial lead at the tricuspid annulus evaluated by 3D echocardiography, the tricuspid leaflet interference assessed by echocardiography, and the degree of slack of the lead on chest x-ray.

Material and Methods

This was a single-centre prospective study. The study was approved by the Research Ethics Board, and all subjects provided written informed consent. We excluded patients with preexisting RV dilatation or dysfunction, patients with more than mild TR, and patients scheduled for cardiac synchronization therapy because pre-existing RV dilatation or dysfunction is frequently present in these patients. The subjects had preprocedural echocardiograms within 48 hours before lead implantation and follow-up echocardiograms at 4 to 6 weeks, 6 months, and 1 year after the procedure. Echocardiograms (both 2-dimensional and 3D) were obtained at each visit, in accordance with the American Society of Echocardiography guidelines., Tricuspid annular plane systolic excursion and RV annular systolic velocity were obtained in addition to left ventricle, right atrium, and RV dimensions. The grading of TR severity was based on existing guidelines. Mild or less TR was categorized into none/trace, mild, and mild-moderate based on the jet area (none/trace < 1.2 cm2, mild 1-3 cm2, mild to moderate 3-5 cm2) to provide a more refined grading so as to enhance our ability to detect evolutional changes of TR severity. The peak TR gradient was calculated using the modified Bernoulli equation, and the right atrium pressure was assessed on the basis of the American Society of Echocardiography guidelines. Three-dimensional images of the tricuspid valve were obtained at the first follow-up visit at 4 to 6 weeks and at 12 months after implantation according to the current guidelines. Both full volume and zoomed 3D volumes were obtained. 3D volumes were analyzed using a commercially available off-line software system (QLab version 10 Philips Healthcare, Andover, MA), and the position of the endocardial lead at the tricuspid annulus level was assessed using the multiplanar reconstruction (MPR) software (Fig. 1; Videos 1-3 , view video online) We used the MPR approach rather than the 3D en face view of the tricuspid valve to determine the position, because we found that the latter generally provided suboptimal images of the tricuspid valve in the setting of nondilated RV. The position was described as commissural (in a commissure) or noncommissural (against a leaflet or centrally located) with reference to the specific commissure or leaflet involved., In addition, potential interference with the tricuspid leaflet motion by the endocardial lead was assessed using both 2-dimensional and 3D echocardiography to specifically assess for impingement, adherence, and entanglement.,,, As previously described, leaflet interference was diagnosed when the systolic excursion of any of the tricuspid leaflets was impeded by the endocardial lead. Impingement was present when the leaflet was not tethered to the lead, whereas direct tethering of the lead to the leaflet was adherence and to the subvalvular chords indicated entanglement (Videos 4-6 , view video online).
Figure 1

Location of the endocardial lead at the tricuspid annulus by multiplanar reconstruction (MPR) analysis based on the 3-dimensional (3D) echocardiographic volume dataset showing the endocardial lead (arrow) at the postero-septal commissure (A) and at the centre position (B). LV, left ventricle; RV, right ventricle.

Location of the endocardial lead at the tricuspid annulus by multiplanar reconstruction (MPR) analysis based on the 3-dimensional (3D) echocardiographic volume dataset showing the endocardial lead (arrow) at the postero-septal commissure (A) and at the centre position (B). LV, left ventricle; RV, right ventricle. All patients had routine postero-anterior and lateral chest x-ray within 2 weeks after endocardial lead implantation. The contour of the lead on chest x-ray was assessed to determine the degree of lead slack and semiquantitated into grade 0 (no slack), grade 1 (minimal slack), grade 2 (normal slack), grade 3 (mildly excessive slack), and grade 4 (very excessive slack) as previously described. The percentage of the RV pacing was determined at the 12-month follow-up by interrogation of the device.

Statistical analysis

Continuous variables were expressed as mean ± standard deviation, and categorical variables were expressed as absolute numbers and percentages. The Student t test was used to compare continuous data in normal distribution, and the Mann–Whitney U test was used for continuous data in skewed distribution. Categorical data were compared using the Fisher or chi-square test. Univariable and multivariable linear regression models were used to assess variables associated with new or worse TR after endocardial lead implantation. A 2-tailed P value < 0.05 was considered statistically significant.

Results

Between February 2013 and June 2015, 153 patients were recruited in the study, and 128 patients completed follow-up at 12 months (mean age of 66.8 ± 12.4 years and 94 women). Atrial fibrillation or flutter was present in 7 patients. A permanent pacemaker was implanted in 61 patients, and an ICD was implanted in 67 patients. New or worse TR developed in 38 patients. Increase in TR severity was by only 1 grade in 32 of 38 patients (84%).

Features of endocardial lead

The 4 lead-specific features in patients with or without new or worse TR are presented in Table 1. Lead position at the commissure was common in both groups. Details of the lead positions at the tricuspid annulus for the 2 groups of patients are shown in Figure 2. Suboptimal 3D images prevented localization of the endocardial leads in 9 patients (1 patient with and 8 patients without new or worse TR). There were no significant differences in lead position at the tricuspid annulus between the 2 groups. Potential tricuspid leaflet interference was identified in 21 patients with impingement being the most common mechanism (Table 1). There were similar portions of ICD in both groups of patients. The slack scores for the 2 groups of patients were also similar. Leaflet interference was associated with the noncommissural lead position, with interference present in 18 of 53 patients with a noncommissural lead position and in 3 of 66 patients with a commissural lead position (P < 0.0001) (Table 2). Leaflet interference was not a specific feature for new TR, because 8 of these patients did not develop new or worse TR. No association was found between the leaflet interference and the slack score or the nature of the lead.
Table 1

Leaflet-specific features in 128 patients

New or worse TR, n = 38 (%)No new or worse TR, n = 90 (%)
Lead position
 Commissural20 (52)46 (51)
 Noncommissural17 (45)36 (40)
 Unable to determine1 (3)8 (9)
Leaflet interference
 Impingement10 (26)6 (7)
 Adherence3 (8)1 (1)
 Entanglement0 (0)1 (1)
 Uncertain1 (3)8 (9)
 No interference24 (63)74 (82)
Nature of lead
 Pacemaker19 (50)42 (47)
 ICD19 (50)48 (53)
Slack score
 00 (0)2 (2)
 18 (21)16 (18)
 223 (60)56 (62)
 36 (16)14 (16)
 41 (3)2 (2)

ICD, implantable cardioverter defibrillator; TR, tricuspid regurgitation.

Figure 2

Endocardial lead positions at the tricuspid annulus in patients with (A) and without (B) worse tricuspid regurgitation (TR) during follow-up.

Table 2

Lead-specific features in 119 patients

Lead interference, n = 21 (%)No lead interference, n = 98 (%)
Lead position
 Commissural3 (14)63 (64)
 Noncommissural18 (86)35 (36)
Nature of lead
 Pacemaker16 (76)37 (38)
 ICD5 (24)61 (62)
Slack score
 00 (0)2 (2)
 13 (14)19 (19)
 214 (67)60 (61)
 33 (14)15 (15)
 41 (5)2 (2)
TR
 New or worse13 (62)24 (24)
 Same8 (38)74 (76)

ICD, implantable cardioverter defibrillator; TR, tricuspid regurgitation.

Leaflet-specific features in 128 patients ICD, implantable cardioverter defibrillator; TR, tricuspid regurgitation. Endocardial lead positions at the tricuspid annulus in patients with (A) and without (B) worse tricuspid regurgitation (TR) during follow-up. Lead-specific features in 119 patients ICD, implantable cardioverter defibrillator; TR, tricuspid regurgitation.

Factors associated with TR

In Table 3, we compared the clinical and echocardiographic variables previously reported to be associated with new or worse TR after endocardial lead implantation in the 2 groups of patients.,,,, Clinical variables including age, sex, and atrial fibrillation were not associated with new TR. The percentages of RV pacing were 19.3% ± 34.0% in patients with and 20.5% ± 37.5% in patients without new or worse TR (P = 0.86). The nature of the lead (pacemaker vs ICD), the lead slack score, the lead position at the annulus by 3D echocardiography, and the leaflet interference were included as variables. Leaflet interference was the only predictor for new TR progression by univariable and multivariable analysis.
Table 3

Univariable and multivariable factors associated with the progression of tricuspid regurgitation during follow-up

VariableUnivariable
Multivariable
CoefficientPCoefficientP
Age0.01330.41
Sex0.0860.35
AF1.220.120.16930.3707
% RV pacing at follow-up0.07880.63
RVFAC0.00390.83
RVSP−0.00260.86
LVEF0.00350.78
ICD lead0.13350.73
Lead slack score0.04440.87
Lead position−0.03700.64
Lead interference−0.25560.0019−0.0840< 0.0001

AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; RV, right ventricle; RVFAC, right ventricular fractional area change; RVSP, right ventricular systolic pressure; TR, tricuspid regurgitation.

Univariable and multivariable factors associated with the progression of tricuspid regurgitation during follow-up AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; RV, right ventricle; RVFAC, right ventricular fractional area change; RVSP, right ventricular systolic pressure; TR, tricuspid regurgitation.

Discussion

We have shown that TR occurred in 30% of patients at 1 year after endocardial lead implantation. In the present study, we prospectively evaluated 4 lead-specific features and found that tricuspid leaflet interference by the endocardial lead was a predictor for new or worse TR, whereas lead position at the tricuspid annulus, nature of lead, and radiological lead slack were not. This finding may be an important factor to consider in developing strategies to present this lead-related complication. Contrary to studies showing development of significant TR within 6 months after device implantation,,,, we have recently shown that development of new or increased TR was common after RV endocardial lead placement at the 12-month follow-up, but the majority of new TR was mild in severity, although it was associated with increases in the dimensions of the right heart chambers. It may be argued that mild TR has little clinical significance, but the progression of TR is a dynamic process, and in the long term there is the likelihood that TR begets TR such that severe TR leading to overt RV failure may ensue in some of these patients who developed new or increased TR. Thus, it is important to identify risk factors and the potential mechanisms for the development of TR in this clinical setting.

Mechanism of TR

The mechanisms of lead-associated TR remain speculative. Patient factors such as atrial fibrillation and left ventricular ejection fraction, and non–lead-related causes such as contraction dyssynchrony due to RV pacing have been reported to predict the development of TR.,, In the present study, patient factors including age, sex, atrial fibrillation, and RV dyssynchrony measured by the percentage of RV pacing were not associated with TR development. Atrial fibrillation is increasingly recognized as a cause for TR,, but our study contained few patients with atrial fibrillation such that the role of atrial fibrillation could not be properly addressed. Furthermore, left ventricle and RV systolic function as evidenced by left ventricular ejection fraction and RV fractional area change did not predict TR progression. Lead-related effects on tricuspid leaflets are likely important and supported by pathologic and intraoperative findings., This is the first prospective study to assess lead-specific factors in the development of TR, and we examined 4 features of the endocardial lead, namely, nature of the lead, lead slack, lead location at the annulus, and echocardiographic evidence of leaflet interference. The last 3 parameters would be potentially amenable for corrective action if found to predict TR. Lead slack assessed the course of the lead within the RV. The degree of lead slack was based on the radiological appearance, which was a measure of the lead distortion or redundancy. Excessive slack may interfere with proper function of the tricuspid annulus or leaflets, but we did not find an association between slack and leaflet interference or TR. This may be explained by the floppy nature of the tricuspid leaflet, which is able to envelop the lead regardless the degree of lead slack. This may also be the reason why the thicker and less flexible ICD leads were not associated with new or worse TR, contrary to the findings of Kim et al. Lead interference appeared more common with pacemaker lead (Table 2), but this finding needs to be interpreted with caution because 8 of 9 patients excluded because of uncertain lead positions were patients with pacemaker leads, and the nature of lead (pacemaker vs ICD) was not a predictor of new TR in the univariable and multivariable analyses (Table 3). Three-dimensional echocardiography is useful in the assessment of the location of the endocardial lead at the level of the tricuspid annulus. Similar to the observation of Seo et al., we showed that the postero-septal commissure was a common location for the endocardial lead in patients with and in those without new or increased TR, in contrast to the finding by Mediratta et al. and Addetia et al., who found no lead-associated TR when the lead was at the central position or postero-septal commissure. In our patients, the postero-septal commissure was the most common location for the endocardial lead and not necessarily a “safe lead position” to avoid the development of TR, although there was an association of lead interference with the noncommissure position. The studies by Mediratta et al. and Addetia et al. were retrospective studies with patient characteristics different from those in our study, and 3D echocardiograms were obtained at 3.9 ± 3.9 years and 3.8 ± 3.0 years, respectively, postimplantation of endocardial lead such that considerable RV remodeling and TV annulus dilatation may have occurred. In the studies by Mediratta et al. and Addetia et al., the presence of leaflet interference was inferred if moderate or greater TR was detected in the presence of an endocardial lead, even though non–lead-related causes might be present. The majority of patients in the study by Mediratta et al. did not have preimplantation echocardiograms, and significant TR was present in many patients who had preimplantation studies. The studies by Mediratta et al. and Addetia et al. included many of the same patients. We agree with Addetia et al. that “a word of caution about the implications of our results for the general population of patients who have pacemakers inserted: this study included a highly selected population.” In our experience, the MPR mode was superior to the 3D en face view of the tricuspid valve in evaluating the position of and leaflet interaction with the endocardial lead. We believe our findings are more representative of the incidence and severity of TR after RV endocardial lead implementation. We found that endocardial lead in the noncommissural position and abutting on the tricuspid leaflet during ventricular systole was not uncommon and did not differentiate patients with TR from those without new or worse TR. We specifically examined for echocardiographic findings of lead interference with leaflet coaptation, and our results would support that these findings provided more reliable evidence of interference with leaflet coaptation than lead position. Nonetheless, 8 of 21 patients with leaflet interference did not develop new TR, likely explained by the redundant nature of the tricuspid leaflets, which have the ability to envelop the endocardial lead and to maintain adequate coaptation. Long-term studies are needed because it is plausible that these patients may develop TR in a longer follow-up.

Study limitations

Although studies have suggested that by 6 months the impact of lead implantation on TR and RV would have been apparent,,,, the time course of TR development and progression after endocardial lead placement is not well defined. A follow-up longer than 1 year will be needed to provide a better appreciation of the long-term effects of TR. Our grading of TR severity to allow a more refined assessment of milder degrees of TR was based largely on the jet area. We believe this was appropriate because other measures of TR, such as jet width and proximal iso-velocity surface area, were not applicable in these cases of mild TR. The validity of the grading method was supported by the observation that a 1-grade increase in TR was associated with unfavorable functional consequences. The differences in grading TR severity need to be considered in comparing our results with results from other studies. We did not find that the position of endocardial lead in relation to the commissures or leaflets to be associated with new or worse TR. It is plausible that the position may have an effect on the development of TR in a longer follow-up because the patients reported by Seo et al. and Addetia et al. were largely studied several years after implantation. Echocardiographic features of tricuspid leaflet interference by the endocardial lead such as those used in the present study have not been well defined or validated. More studies are needed to evaluate these echocardiographic features on short-term and long-term effects on tricuspid valve function.

Conclusions

New or increased TR occurred in 30% of patients after RV endocardial lead implantation at a follow-up of 1 year. The implantation of an ICD lead was not associated with TR compared with the implantation of a pacemaker lead. Echocardiographic evidence of leaflet interference, not the lead position at the tricuspid annulus or lead slack, was a predictor of new or worse TR at follow-up of 1 year. Leaflet interference was associated with a noncommissural lead position. A longer-term follow-up is needed to assess the progression and clinical impact of endocardial lead-associated TR. Studies are also needed to evaluate the effect on TR development by modification of the lead implantation technique to minimize tricuspid leaflet interference.

Funding Sources

Supported in part by the Ontario Ministry of Health Innovation Fund.

Disclosures

The authors have no conflicts of interest to disclose.
  33 in total

1.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

Authors:  Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2010-07       Impact factor: 5.251

2.  Effects of pacemaker and implantable cardioverter defibrillator electrodes on tricuspid regurgitation and right sided heart functions.

Authors:  Peyman Arabi; Necla Özer; Ahmet Hakan Ateş; Hikmet Yorgun; Ali Oto; Kudret Aytemir
Journal:  Cardiol J       Date:  2015-09-28       Impact factor: 2.737

Review 3.  Tricuspid Valve Dysfunction Following Pacemaker or Cardioverter-Defibrillator Implantation.

Authors:  James D Chang; Warren J Manning; Elisa Ebrille; Peter J Zimetbaum
Journal:  J Am Coll Cardiol       Date:  2017-05-09       Impact factor: 24.094

4.  Prevalence and Significance of Tricuspid Regurgitation Post-Endocardial Lead Placement.

Authors:  Kalilur Anvardeen; Rajeev Rao; Samir Hazra; Karen Hay; Hongyan Dai; Nik Stoyanov; David Birnie; Girish Dwivedi; Kwan Leung Chan
Journal:  JACC Cardiovasc Imaging       Date:  2018-09-12

5.  Effect of Right Ventricular Pacing on Right Ventricular Mechanics and Tricuspid Regurgitation in Patients With High-Grade Atrioventricular Block and Sinus Rhythm (from the Protection of Left Ventricular Function During Right Ventricular Pacing Study).

Authors:  Makoto Saito; Andrea Iannaccone; Gerry Kaye; Kazuaki Negishi; Wojciech Kosmala; Thomas H Marwick
Journal:  Am J Cardiol       Date:  2015-10-09       Impact factor: 2.778

6.  3D echocardiographic location of implantable device leads and mechanism of associated tricuspid regurgitation.

Authors:  Anuj Mediratta; Karima Addetia; Megan Yamat; Joshua D Moss; Hemal M Nayak; Martin C Burke; Lynn Weinert; Francesco Maffessanti; Valluvan Jeevanandam; Victor Mor-Avi; Roberto M Lang
Journal:  JACC Cardiovasc Imaging       Date:  2014-03-13

7.  Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation.

Authors:  Caroline M Van De Heyning; Esam Elbarasi; Simona Masiero; Michela Brambatti; Sami Ghazal; Said Al-Maashani; Alessandro Capucci; Darryl Leong; Bharati Shivalkar; Johan B Saenen; Hielko P Miljoen; Carlos A Morillo; Syamkumar Divarakarmenon; Guy Amit; Sebastian Ribas; Erika Baiocco; Alessandro Maolo; Andrea Romandini; Simone Maffei; Stuart J Connolly; Jeff S Healey; Hisham Dokainish
Journal:  Can J Cardiol       Date:  2018-11-29       Impact factor: 5.223

8.  Tricuspid insufficiency does not increase early after permanent implantation of pacemaker leads.

Authors:  Nezihi Kucukarslan; Ata Kirilmaz; Eralp Ulusoy; Mehmet Yokusoglu; Nikola Gramatnikovski; Ertugrul Ozal; Harun Tatar
Journal:  J Card Surg       Date:  2006 Jul-Aug       Impact factor: 1.620

9.  The effects of right ventricular apical pacing with transvenous pacemaker and implantable cardioverter defibrillator on mitral and tricuspid regurgitation.

Authors:  Zaher Fanari; Sumaya Hammami; Muhammad Baraa Hammami; Safa Hammami; Mossaab Shuraih
Journal:  J Electrocardiol       Date:  2015-07-07       Impact factor: 1.438

10.  Clinical utility of 3-dimensional echocardiography in the evaluation of tricuspid regurgitation caused by pacemaker leads.

Authors:  Yoshihiro Seo; Tomoko Ishizu; Hideki Nakajima; Yukio Sekiguchi; Shigeyuki Watanabe; Kazutaka Aonuma
Journal:  Circ J       Date:  2008-09       Impact factor: 2.993

View more
  1 in total

1.  Lead Dependent Tricuspid Valve Dysfunction-Risk Factors, Improvement after Transvenous Lead Extraction and Long-Term Prognosis.

Authors:  Anna Polewczyk; Wojciech Jacheć; Dorota Nowosielecka; Andrzej Tomaszewski; Wojciech Brzozowski; Dorota Szczęśniak-Stańczyk; Krzysztof Duda; Andrzej Kutarski
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.